Chronic Obstructive Pulmonary Disease (COPD) Clinical Trial
— EOSOfficial title:
Effect of Roflumilast in COPD Patients Treated With Salmeterol. A 24-week, Double-blind Study With 500 μg Roflumilast Once Daily Versus Placebo. The EOS Study
The aim of the study is to compare the efficacy of roflumilast on pulmonary function and symptomatic parameters in patients with chronic obstructive pulmonary disease (COPD) during concomitant administration of salmeterol. The study duration will last up to 28 weeks. The study will provide further data on safety and tolerability of roflumilast.
Status | Completed |
Enrollment | 933 |
Est. completion date | February 2008 |
Est. primary completion date | July 2007 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 40 Years and older |
Eligibility |
Main Inclusion Criteria: - History of COPD for at least 12 months prior to baseline visit - FEV1/FVC ratio (post-bronchodilator) = 70% - FEV1 (post-bronchodilator) between = 40% and = 70% of predicted Main Exclusion Criteria: - COPD exacerbation indicated by a treatment with systemic glucocorticosteroids and/or antibiotics not stopped at least 4 weeks prior to baseline visit |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Austria | Altana Pharma/Nycomed Investigational Site | Linz | |
Austria | Altana Pharma/Nycomed Investigational Site | Neusiedl/See | |
Austria | Altana Pharma/Nycomed Investigational Site | Perg | |
Austria | Altana Pharma/Nycomed Investigational Site | Salzburg | |
Austria | Altana Pharma/Nycomed Investigational Site | St. Pölten | |
Austria | Altana Pharma/Nycomed Investigational Site | Steyr | |
Austria | Altana Pharma/Nycomed Investigational Site | Wien | |
Austria | Altana Pharma/Nycomed Investigational Site | Wien | |
Austria | Altana Pharma/Nycomed Investigational Site | Wien | |
Austria | Altana Pharma/Nycomed Investigational Site | Wiener Neustadt | |
Austria | Altana Pharma/Nycomed Investigational Site | Zwettl | |
Belgium | Altana Pharma/Nycomed Investigational Site | Arlon | |
Belgium | Altana Pharma/Nycomed Investigational Site | Bruxelles | |
Belgium | Altana Pharma/Nycomed Investigational Site | Bruxelles | |
Belgium | Altana Pharma/Nycomed Investigational Site | Duffel | |
Belgium | Altana Pharma/Nycomed Investigational Site | Genk | |
Belgium | Altana Pharma/Nycomed Investigational Site | Gilly | |
Belgium | Altana Pharma/Nycomed Investigational Site | Halen | |
Belgium | Altana Pharma/Nycomed Investigational Site | Jette | |
Belgium | Altana Pharma/Nycomed Investigational Site | Leuven | |
Belgium | Altana Pharma/Nycomed Investigational Site | Liège | |
Belgium | Altana Pharma/Nycomed Investigational Site | Malmedy | |
Belgium | Altana Pharma/Nycomed Investigational Site | Montigny-Le-Tilleul | |
Belgium | Altana Pharma/Nycomed Investigational Site | Namur | |
Belgium | Altana Pharma/Nycomed Investigational Site | Veurne | |
Canada | Altana Pharma/Nycomed Investigational Site | Ajax, Ontario | |
Canada | Altana Pharma/Nycomed Investigational Site | Halifax, N.S. | |
Canada | Altana Pharma/Nycomed Investigational Site | Hamilton | |
Canada | Altana Pharma/Nycomed Investigational Site | Hamilton, Ontario | |
Canada | Altana Pharma/Nycomed Investigational Site | Laval | |
Canada | Altana Pharma/Nycomed Investigational Site | London | |
Canada | Altana Pharma/Nycomed Investigational Site | Mirabel | |
Canada | Altana Pharma/Nycomed Investigational Site | Montreal | |
Canada | Altana Pharma/Nycomed Investigational Site | Montreal | |
Canada | Altana Pharma/Nycomed Investigational Site | Montreal, PQ | |
Canada | Altana Pharma/Nycomed Investigational Site | New Market, ON | |
Canada | Altana Pharma/Nycomed Investigational Site | North Bay | |
Canada | Altana Pharma/Nycomed Investigational Site | Ontario | |
Canada | Altana Pharma/Nycomed Investigational Site | Ottawa | |
Canada | Altana Pharma/Nycomed Investigational Site | Quebec City | |
Canada | Altana Pharma/Nycomed Investigational Site | Regina, Saskatchewan | |
Canada | Altana Pharma/Nycomed Investigational Site | Saint John | |
Canada | Altana Pharma/Nycomed Investigational Site | Sainte-Foy, Quebec | |
Canada | Altana Pharma/Nycomed Investigational Site | Saskatoon SK | |
Canada | Altana Pharma/Nycomed Investigational Site | Sherbrooke, PQ | |
Canada | Altana Pharma/Nycomed Investigational Site | Toronto, ON | |
Canada | Altana Pharma/Nycomed Investigational Site | Toronto, ON | |
Canada | Altana Pharma/Nycomed Investigational Site | Vancouver, BC | |
Canada | Altana Pharma/Nycomed Investigational Site | Windsor | |
Canada | Altana Pharma/Nycomed Investigational Site | Winnipeg MB | |
Canada | Altana Pharma/Nycomed Investigational Site | Woodstock | |
France | Altana Pharma/Nycomed Investigational Site | Beausoleil | |
France | Altana Pharma/Nycomed Investigational Site | Beuvry | |
France | Altana Pharma/Nycomed Investigational Site | Chauny Cedex | |
France | Altana Pharma/Nycomed Investigational Site | Grasse | |
France | Altana Pharma/Nycomed Investigational Site | Grenoble | |
France | Altana Pharma/Nycomed Investigational Site | Lille Cedex | |
France | Altana Pharma/Nycomed Investigational Site | Lyon | |
France | Altana Pharma/Nycomed Investigational Site | Martigues Cedex | |
France | Altana Pharma/Nycomed Investigational Site | Montpellier Cedex | |
France | Altana Pharma/Nycomed Investigational Site | Nantes | |
France | Altana Pharma/Nycomed Investigational Site | Nice | |
France | Altana Pharma/Nycomed Investigational Site | Nice Cedex 1 | |
France | Altana Pharma/Nycomed Investigational Site | Nimes | |
France | Altana Pharma/Nycomed Investigational Site | Saint Laurent Du Var | |
France | Altana Pharma/Nycomed Investigational Site | Saint-Quentin | |
France | Altana Pharma/Nycomed Investigational Site | Trelaze | |
Germany | Altana Pharma/Nycomed Investigational Site | Aschaffenburg | |
Germany | Altana Pharma/Nycomed Investigational Site | Bochum | |
Germany | Altana Pharma/Nycomed Investigational Site | Bonn | |
Germany | Altana Pharma/Nycomed Investigational Site | Geesthacht | |
Germany | Altana Pharma/Nycomed Investigational Site | Gelnhausen | |
Germany | Altana Pharma/Nycomed Investigational Site | Großhansdorf | |
Germany | Altana Pharma/Nycomed Investigational Site | Hannover | |
Germany | Altana Pharma/Nycomed Investigational Site | Koblenz | |
Germany | Altana Pharma/Nycomed Investigational Site | Köln | |
Germany | Altana Pharma/Nycomed Investigational Site | Marburg | |
Germany | Altana Pharma/Nycomed Investigational Site | Saarbruecken | |
Germany | Altana Pharma/Nycomed Investigational Site | Schwetzingen | |
Germany | Altana Pharma/Nycomed Investigational Site | Sinsheim | |
Germany | Altana Pharma/Nycomed Investigational Site | Surwold | |
Germany | Altana Pharma/Nycomed Investigational Site | Witten | |
Germany | Altana Pharma/Nycomed Investigational Site | Würzburg | |
Italy | Altana Pharma/Nycomed Investigational Site | Bari | |
Italy | Altana Pharma/Nycomed Investigational Site | Bologna | |
Italy | Altana Pharma/Nycomed Investigational Site | Catania | |
Italy | Altana Pharma/Nycomed Investigational Site | Cisanello (PI) | |
Italy | Altana Pharma/Nycomed Investigational Site | Genova | |
Italy | Altana Pharma/Nycomed Investigational Site | Livorno | |
Italy | Altana Pharma/Nycomed Investigational Site | Milano | |
Italy | Altana Pharma/Nycomed Investigational Site | Pordenone | |
Italy | Altana Pharma/Nycomed Investigational Site | Roma | |
Italy | Altana Pharma/Nycomed Investigational Site | Saluzzo (CN) | |
Italy | Altana Pharma/Nycomed Investigational Site | Torino | |
Italy | Altana Pharma/Nycomed Investigational Site | Tradate (VA) | |
Italy | Altana Pharma/Nycomed Investigational Site | Verona | |
Italy | Altana Pharma/Nycomed Investigational Site | Vittorio Veneto (TV) | |
Netherlands | Altana Pharma/Nycomed Investigational Site | Alkmaar | |
Netherlands | Altana Pharma/Nycomed Investigational Site | Almelo | |
Netherlands | Altana Pharma/Nycomed Investigational Site | Eindhoven | |
Netherlands | Altana Pharma/Nycomed Investigational Site | Helmond | |
Netherlands | Altana Pharma/Nycomed Investigational Site | Schiedam | |
Netherlands | Altana Pharma/Nycomed Investigational Site | Zwolle | |
South Africa | Altana Pharma/Nycomed Investigational Sites | Kapstadt | |
Spain | Altana Pharma/Nycomed Investigational Site | Alicante | |
Spain | Altana Pharma/Nycomed Investigational Site | Barcelona | |
Spain | Altana Pharma/Nycomed Investigational Site | Barcelona | |
Spain | Altana Pharma/Nycomed Investigational Site | Barcelona | |
Spain | Altana Pharma/Nycomed Investigational Site | Barcelona | |
Spain | Altana Pharma/Nycomed Investigational Site | Elche (Alicante) | |
Spain | Altana Pharma/Nycomed Investigational Site | Fuentesnuevas, Ponferrada (León) | |
Spain | Altana Pharma/Nycomed Investigational Site | Guadalajara | |
Spain | Altana Pharma/Nycomed Investigational Site | Laredo (Cantabria) | |
Spain | Altana Pharma/Nycomed Investigational Site | Mataró, Barcelona | |
Spain | Altana Pharma/Nycomed Investigational Site | Petrer (Alicante) | |
Spain | Altana Pharma/Nycomed Investigational Site | Sabadell | |
Spain | Altana Pharma/Nycomed Investigational Site | Tarrasa (Barcelona) | |
Spain | Altana Pharma/Nycomed Investigational Site | Torrelavega (Cantabria) | |
United Kingdom | Altana Pharma/Nycomed Investigational Site | Belfast | |
United Kingdom | Altana Pharma/Nycomed Investigational Site | Belfast | |
United Kingdom | Altana Pharma/Nycomed Investigational Site | Belfast | |
United Kingdom | Altana Pharma/Nycomed Investigational Site | Bexhill-on-Sea, East Sussex | |
United Kingdom | Altana Pharma/Nycomed Investigational Site | Bradford | |
United Kingdom | Altana Pharma/Nycomed Investigational Site | Bradford on Avon, Wiltshire | |
United Kingdom | Altana Pharma/Nycomed Investigational Site | Chesterfield Derbyshire | |
United Kingdom | Altana Pharma/Nycomed Investigational Site | Coleraine | |
United Kingdom | Altana Pharma/Nycomed Investigational Site | Cookstown | |
United Kingdom | Altana Pharma/Nycomed Investigational Site | East Sussex | |
United Kingdom | Altana Pharma/Nycomed Investigational Site | Edinburg | |
United Kingdom | Altana Pharma/Nycomed Investigational Site | Glasgow | |
United Kingdom | Altana Pharma/Nycomed Investigational Site | Hastings | |
United Kingdom | Altana Pharma/Nycomed Investigational Site | Middlessex | |
United Kingdom | Altana Pharma/Nycomed Investigational Site | Sunbury on Thames, Middlessex | |
United Kingdom | Altana Pharma/Nycomed Investigational Site | Watford |
Lead Sponsor | Collaborator |
---|---|
Takeda |
Austria, Belgium, Canada, France, Germany, Italy, Netherlands, South Africa, Spain, United Kingdom,
Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, Rabe KF; M2-127 and M2-128 study groups. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clin — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1) | Mean change from baseline during the treatment period in pre-bronchodilator FEV1 [L] | Change from baseline over 24 weeks of treatment | No |
Secondary | Post-bronchodilator FEV1 | Mean change from baseline during the treatment period in post-bronchodilator FEV1 [L] | Change from baseline over 24 weeks of treatment | No |
Secondary | COPD Exacerbation Rate (Mild, Moderate or Severe) | Mean rate of COPD exacerbations requiring rescue medication of 3 or more puffs/day on at least 2 consecutive days (=mild COPD exacerbations), or requiring oral or parenteral glucocorticosteroids (=moderate COPD exacerbations), or requiring hospitalization, or leading to death (=severe COPD exacerbations), per patient per year. A COPD exacerbation is an event in the natural course of the disease characterized by a change in the patient's baseline dyspnea, cough and/or sputum beyond day-to-day variability sufficient to warrant a change in management [ATS / ERS 2005]. |
24 weeks treatment period | No |
Secondary | Transition Dyspnea Index (TDI) Focal Score | The TDI is a recognized questionnaire to measure dyspnea in an out patient COPD population. At baseline, 3 components of dyspnea, each graded with 4 questions, were asked: Functional Impairment Magnitude of Task Magnitude of Effort At each of the post-randomization visits questions from the TDI were asked related to 3 components: Change in Functional Impairment Magnitude of Task Magnitude of Effort Each question in the TDI is graded from -3 (major deterioration) to +3 (major improvement). This results in a TDI Focal Score ranging from -9 to +9. |
Change from baseline over 24 weeks of treatment | No |
Secondary | Shortness of Breath Questionnaire (SOBQ) Total Score | Mean change from baseline during the treatment period in SOBQ. This is a 24-item measure that assesses self-reported shortness of breath while performing a variety of activities of daily living. The questions were administered at visits V0, V2, V3, V4, V5, V6 and Vend to assess the perceived shortness of breath of the patient. For each activity listed in the questionnaire the patient should rate his/her breathlessness on a scale between zero and five, where zero is "not at all breathless" and five is "maximally breathless or too breathless to do the activity". |
Change from baseline over 24 weeks of treatment | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03282019 -
Study of Long-term HFNC for COPD Patients With HOT
|
N/A | |
Completed |
NCT05573464 -
A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With the Hydrofluoroolefin Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
|
Phase 3 | |
Recruiting |
NCT06040086 -
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
|
Phase 3 | |
Not yet recruiting |
NCT06376994 -
Multi-Center Clean Air Randomized Controlled Trial in COPD
|
Phase 3 | |
Completed |
NCT02728674 -
Management of Patients With Respiratory Symptoms in Sweden
|
N/A | |
Completed |
NCT02797392 -
Feasibility of a Preventive Program Against Lifestyle Related Diseases
|
N/A | |
Completed |
NCT02926534 -
Cross-Sectional Study of COPD Prevalence Among Smokers, Ex-smokers and Never-Smokers in Almaty, Kazakhstan
|
N/A | |
Recruiting |
NCT02415478 -
Bronchioscopic Lung Volume Reduction (BLVR)
|
N/A | |
Completed |
NCT02774226 -
Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Completed |
NCT02512510 -
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT02518139 -
A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT02459080 -
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT03487406 -
Anti-platelet Therapy in the Prevention of Cardiovascular Disease in Patients With COPD (APPLE-COPD: ICON 2)
|
Phase 2 | |
Completed |
NCT01908140 -
Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT01615484 -
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
|
N/A | |
Withdrawn |
NCT01908933 -
Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema
|
Phase 3 | |
Completed |
NCT01893476 -
A Pragmatic Cluster Trial of a Tailored Intervention to Improve COPD Management
|
N/A | |
Completed |
NCT01701869 -
Microbiology & Immunology of the Chronically-inflamed Airway
|
N/A | |
Recruiting |
NCT02527486 -
Seoul National University Airway Registry
|
N/A | |
Withdrawn |
NCT01377428 -
Efficacy of Indacaterol 150 µg Versus Formoterol
|
Phase 4 |